Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 5/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | SMPD2 | O60906 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.34 |
| ▸ | ITGAL | P20701 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21434036 | 1.00 | SMPD3 (0.39) | SMPD3SYKSSTR1SSTR4SMPD2 | |
| SCHEMBL21434037 | 1.00 | SMPD3 (0.39) | SMPD3SYKSSTR1SSTR4SMPD2 | |
| SCHEMBL21434059 | 0.93 | SMPD3 (0.40) | SMPD3SYKSSTR1SSTR4GRM2 | |
| SCHEMBL21434056 | 0.93 | SMPD3 (0.40) | SMPD3SYKSSTR1SSTR4GRM2 | |
| SCHEMBL21452696 | 0.93 | SMPD3 (0.40) | SMPD3SYKSSTR1SSTR4GRM2 | |
| SCHEMBL21452656 | 0.92 | SMPD3 (0.39) | SMPD3SYKSSTR1SSTR4GRM2 | |
| SCHEMBL21452494 | 0.89 | SMPD3 (0.47) | SMPD3SYKEPHX2ABL1 | |
| SCHEMBL21433981 | 0.89 | SMPD3 (0.47) | SMPD3SYKEPHX2ABL1 | |
| SCHEMBL21433979 | 0.89 | SMPD3 (0.47) | SMPD3SYKEPHX2ABL1 | |
| SCHEMBL21434131 | 0.88 | ITGB2 (0.45) | SMPD3SYKSSTR1SSTR4SMPD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | SMPD3 4779/4885SYK 923/4885SSTR1 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.